Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/976"
| Predicate | Value (sorted: default) |
|---|---|
| rdfs:label | |
| rdf:type | |
| ?:Evidence_enzyme_system | |
| ?:Evidence_numb_subjects | |
| ?:Evidence_object_dose | |
| ?:Evidence_precip_dose | |
| ?:Evidence_type | |
| ?:Evidence_value | |
| ?:content |
"Route of administration: oral
study duration: a single 10mg reference dose of atorvastatin, 2 wk washout, then 12 days erythromycin (500mg qid) with a single 10mg dose on day 7 of atorvastatin
population: 12 healthy adults (on withdrew before study completion_
male: 8
female: 4
ages: 22-57 years
AUC_i/AUC: 167/126 ng*hr/ml = 1.325 (CI: 5.9 to 65.4)
NOTE: The 0-infinity AUC values were used
Quote:
"
The effect of erythromycin on the pharmacokinetics of atorvastatin, an inhibitor of HMG-CoA reductase, was investigated in 12 healthy volunteers. Each subject received a single 10 mg dose of atorvastatin on two separate occasions, separated by 2 weeks. Erythromycin (500 mg qid) was given from 7 days before through 4 days after the second atorvastatin dose. Atorvastatin concentrations were determined by an enzyme inhibition assay, which measured both atorvastatin and active metabolites. When erythromycin was coadministered with atorvastatin, mean Cmax and AUC(0-infinity) increased by 37.7% and 32.5%, respectively. Mean terminal half-life was similar following each atorvastatin dose. Possible mechanisms for this interaction include erythromycin inhibition of first-pass conversion of atorvastatin to inactive metabolites and erythromycin inhibition of P-glycoprotein-mediated intestinal or biliary secretion.""
|
| dc:creator | |
| dc:date |
"10/16/2007 09:50:31"
|
| rdfs:seeAlso |
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ erythromycin_increases_auc_atorvastatin, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1760 }